Topical cyclosporine-containing preparations and their use

Stable cyclosporine formulations with nanomicelles address side effects and handling issues, ensuring safety and efficacy in ophthalmic use.

JP7864788B2Active Publication Date: 2026-05-25SUN PHARMACEUTICAL INDUSTRIES LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024146154
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-03-21
Filing Date
2024-08-28
Publication Date
2026-05-25
Estimated Expiration
2037-02-28

AI Technical Summary

Technical Problem

Existing ophthalmic formulations containing cyclosporine suffer from side effects such as reduced vision, increased tearing, eye grease, and dysgeusia, and are not stable during handling and at elevated temperatures.

Method used

Formulations containing 0.087 to 0.093% cyclosporine, with nanomicelles of specific particle sizes, are developed, which are stable at elevated temperatures and free of organic solvents, preserving a clear aqueous solution without preservatives.

Benefits of technology

The formulations provide a better safety profile with reduced side effects and improved handling properties, maintaining stability during industrial-scale manufacturing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007864788000001
    Figure 0007864788000001
Patent Text Reader

Abstract

To provide a topical ophthalmic preparation containing cyclosporin, and a method for producing the preparation.SOLUTION: A topical ophthalmic preparation contains 0.087 to 0.093 wt.% of cyclosporin. In some aspects and embodiments, the preparation may contain polyoxyl lipid or fatty acid and / or polyalkoxylated alcohol, and may contain nanomicelle.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Topical formulations and their uses

    JP2018532809A

  • OPHTHALMIC COMPOSITIONS COMPRISING CALCINEURIN INHIBITORS OR mTOR INHIBITORS

    US20090092665A1

  • Binding of pathological forms of proteins using conjugated polyelectrolytes

    US20100310462A1

  • Topical formulations and uses thereof

    US20140057854A1

  • Topical aqueous nanomicellar, ophthalmic solutions and uses thereof

    US8980839B2